Kezar Life Sciences (KZR) Expected to Announce Earnings on Tuesday

Kezar Life Sciences (NASDAQ:KZR) is expected to issue its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($1.39) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, April 3, 2026 at 9:30 AM ET.

Kezar Life Sciences Price Performance

KZR stock opened at $6.43 on Tuesday. The business’s 50-day moving average price is $6.50 and its 200-day moving average price is $5.85. The stock has a market cap of $47.07 million, a P/E ratio of -0.76 and a beta of 0.53. The company has a quick ratio of 7.06, a current ratio of 7.07 and a debt-to-equity ratio of 0.02. Kezar Life Sciences has a twelve month low of $3.53 and a twelve month high of $7.45.

Institutional Trading of Kezar Life Sciences

Several institutional investors have recently made changes to their positions in the business. Landscape Capital Management L.L.C. purchased a new position in Kezar Life Sciences in the 3rd quarter worth approximately $51,000. Woodline Partners LP purchased a new stake in Kezar Life Sciences during the 1st quarter valued at approximately $125,000. Torno Capital LLC bought a new stake in shares of Kezar Life Sciences during the fourth quarter valued at approximately $126,000. Dimensional Fund Advisors LP raised its position in shares of Kezar Life Sciences by 14.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock valued at $167,000 after buying an additional 3,312 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Kezar Life Sciences by 28.4% in the fourth quarter. State Street Corp now owns 27,093 shares of the company’s stock worth $170,000 after buying an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Kezar Life Sciences in a research note on Monday, December 22nd. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $6.00.

Kezar Life Sciences Company Profile

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.